Evidence map›Paper›PMID 36115364›Full record

ReviewThe Lancet. Neurology2022

Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments.

Melissa A Elafros, Henning Andersen, David L Bennett, Masha G Savelieff, Vijay Viswanathan, Brian C Callaghan, Eva L Feldman

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
209citing papers in PubMed, 10 pooled it
33.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

209 citing papers in PubMed, 10 syntheses or guidelines pooled it, 309 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Alpha-lipoic acid for diabetic peripheral neuropathy.The Cochrane database of systematic reviews · 2024
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Glial cells in neuropathic pain.Physiological reviews · 2026
    Review
  18. Article
  19. Article
  20. Review

149 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Melissa A ElafrosDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.
Henning AndersenDepartment of Neurology, Aarhus University Hospital, Aarhus, Denmark.
David L BennettNuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.
Masha G SavelieffDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.
Vijay ViswanathanMV Hospital for Diabetes and Prof M Viswanathan Diabetes Research Centre, Royapuram, Chennai, India.
Brian C CallaghanDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.
Eva L FeldmanDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA. Electronic address: efeldman@umich.edu.
University of Michigan · USAarhus University Hospital · DKM.V. Hospital for Diabetes and Diabetes Research Centre · INUniversity of Oxford · GB

Funding

Pilot and Feasibility ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 to 2025
$4.9M
Pilot and Feasibility (P and F) ProgramP30DK089503 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$1.2M
Pilot and Feasibility ProgramP30DK092926 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$779k
GASTROINTESTINAL CANCER SCREENING AND SURVEILLANCEK24DK002926 · DUKE UNIVERSITY · 2000 to 2005
$591k
Identifying lifelong factors that impact brain health and outcomes in type 1 diabetes: The Cognition and Longitudinal Assessments of Risk Factors over 30 Years (CLARiFY) Diabetes Complications StudyR01DK129320 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$442k
Medical Research Council MR/T020113/1Medical Research Council MR/W002388/1NCATS NIH HHS UL1 TR002240NIDDK NIH HHS K24 DK002926NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK089503NIDDK NIH HHS P30 DK092926NIDDK NIH HHS R01 DK115687NIDDK NIH HHS R01 DK129320NIDDK NIH HHS R24 DK082841NINDS NIH HHS R21 NS102924NINDS NIH HHS R25 NS089450
6 · The paper itself

Abstract

Diabetic peripheral neuropathy (DPN) occurs in up to half of individuals with type 1 or type 2 diabetes. DPN results from the distal-to-proximal loss of peripheral nerve function, leading to physical disability and sometimes pain, with the consequent lowering of quality of life. Early diagnosis improves clinical outcomes, but many patients still develop neuropathy. Hyperglycaemia is a risk factor and glycaemic control prevents DPN development in type 1 diabetes. However, glycaemic control has modest or no benefit in individuals with type 2 diabetes, probably because they usually have comorbidities. Among them, the metabolic syndrome is a major risk factor for DPN. The pathophysiology of DPN is complex, but mechanisms converge on a unifying theme of bioenergetic failure in the peripheral nerves due to their unique anatomy. Current clinical management focuses on controlling diabetes, the metabolic syndrome, and pain, but remains suboptimal for most patients. Thus, research is ongoing to improve early diagnosis and prognosis, to identify molecular mechanisms that could lead to therapeutic targets, and to investigate lifestyle interventions to improve clinical outcomes.

Indexed as

Diabetes Mellitus, Type 2Diabetic NeuropathiesMetabolic SyndromeHumansPainQuality of Life

Identifiers

PMID36115364
PMCPMC10112836
OpenAlexW4296123999

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.